Aligos Therapeutics, Inc. (ALGS) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ALGS Revenue Growth
ALGS Revenue Analysis (2018–2025)
As of May 8, 2026, Aligos Therapeutics, Inc. (ALGS) generated trailing twelve-month (TTM) revenue of $1.9 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, ALGS's historical revenue data shows a 3-year CAGR of -46.0%. The company achieved its highest annual revenue of $15.5 million in 2023.
When compared to Healthcare sector peers including ARWR (+14.1% YoY), HALO (+37.6% YoY), and RCUS (+67.4% YoY), ALGS has underperformed the peer group in terms of revenue growth. Compare ALGS vs ARWR →
ALGS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ALGSCurrent | $2M | -100.0% | - | -4024.9% | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 GILD | $29.4B | +3.5% | +3.6% | 40.1% | |
 VRTX | $12.1B | +10.4% | +14.2% | 39.4% |
ALGS Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.2M | -44.6% | $1.3M | 57.5% | $-87,985,000 | -4024.9% |
| 2024 | $3.9M | -74.6% | $3.9M | 100.0% | $-89,154,000 | -2259.9% |
| 2023 | $15.5M | +11.7% | $15.5M | 100.0% | $-88,127,000 | -567.5% |
| 2022 | $13.9M | +219.0% | $13.9M | 100.0% | $-97,580,000 | -701.7% |
| 2021 | $4.4M | - | $4.4M | 100.0% | $-128,321,000 | -2943.8% |
| 2020 | $0 | - | $-3,325,000 | - | $-97,834,000 | - |
| 2019 | $0 | - | $-2,299,000 | - | $-54,043,000 | - |
| 2018 | $0 | - | $-1,291,000 | - | $-13,661,000 | - |
See ALGS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALGS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALGS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonALGS — Frequently Asked Questions
Quick answers to the most common questions about buying ALGS stock.
Is ALGS's revenue growth accelerating or slowing?
ALGS revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $2M. This reverses the prior growth trend.
What is ALGS's long-term revenue growth rate?
Aligos Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is ALGS's revenue distributed by segment?
ALGS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.